Pelvic Radiotherapy Brought No Benefit in High-Risk Localized Prostate Cancer: GETUG 12 Trial

Pelvic Radiotherapy Brought No Benefit in High-Risk Localized Prostate Cancer: GETUG 12 Trial

09/05/2015

BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared wi

BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared with those who had prostate radiation only. That was the finding of a sub-analysis of 358 patients from the GETUG 12 phase-III trial treated with primary radiotherapy. Study author Pierre Blanchard MD PhD, from Gustave Roussy in Villejuif, France, gave Oncology Times reporter Sarah Maxwell the details after he presented the results to the 3rd ESTRO Forum (April 24-28, 2015).